Engineering immune cells to kill cancer

Results have been released for Malaghan Institute's ground-breaking CAR T-cell cancer therapy trial, and they are promising. The therapy reprogrammes a patient's own immune cells to recognise and kill cancer. Discussing the treatment and trial are Professor Carl June from the University of Pennsylvania who pioneered the therapy and Dr Robert Weinkove, who leads Malaghan's CAR T-cell programme. They are joined by writer and poet Michele Leggott, who is twelve months into the trial, for an update on her progress.